checkAd
    Startseite > Aktien > Editas Medicine > Nachrichten
    Editas Medicine Aktie
    5,6700
     
    USD
    +0,89 %
    +0,0500 USD
    Letzter Kurs 02:00:00 Nasdaq
    5,6600
     
    USD
    18.300 STK
    Geldkurs 03.05.24
    5,6700
     
    USD
    800 STK
    Briefkurs 03.05.24
    ISIN: US28106W1036 · WKN: A2AC4K · SYM: EDIT · USA

    Neueste Nachrichten

    Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
    02.05.24 · globenewswire · Editas Medicine
    Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
    01.05.24 · globenewswire · Editas Medicine
    Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
    22.04.24 · globenewswire · Editas Medicine
    Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
    28.02.24 · globenewswire · Editas Medicine
    Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
    21.02.24 · globenewswire · Editas Medicine
    Editas Medicine to Participate in Upcoming Investor Conferences
    31.01.24 · globenewswire · Editas Medicine
    Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
    08.01.24 · globenewswire · Editas Medicine
    Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    03.01.24 · globenewswire · Editas Medicine
    Editas Medicine Announces Third Quarter 2023 Results and Business Updates
    03.11.23 · globenewswire · Editas Medicine
    Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
    02.11.23 · globenewswire · Editas Medicine
    Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
    27.10.23 · globenewswire · Editas Medicine
    Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
    16.10.23 · globenewswire · Editas Medicine